Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor–induced colitis
Hamzah Abu‐Sbeih(The University of Texas MD Anderson Cancer Center), Yinghong Wang(Hangzhou Center for Disease Control and Prevention), Faisal S. Ali(Beth Israel Deaconess Medical Center), Niharika Mallepally(University of California, Los Angeles), Ellie Chen(Baylor College of Medicine), Mehmet Altan(The University of Texas MD Anderson Cancer Center), Aline Charabaty(Georgetown University), Ramona Dadu(The University of Texas MD Anderson Cancer Center), Xuemei Wang(First Affiliated Hospital of Zhengzhou University), Amir A. Jazaeri(The University of Texas MD Anderson Cancer Center), Bret A. Lashner(Cleveland Clinic), Robert S. Bresalier(The University of Texas MD Anderson Cancer Center)
Cited by 190
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
|Proceedings of the National Academy of Sciences|2003|2k
Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial
|Controlled Clinical Trials|2000|1k
Colorectal-Cancer Incidence and Mortality with Screening Flexible Sigmoidoscopy
|New England Journal of Medicine|2012|1k
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|560